A Review of “Bath Salts”: Evolving Designer Drugs of Abuse

REFERENCES

• Advisory Council on the Misuse of Drugs. (2012). Consideration of the cathinones. Retrieved from www.gov.uk
   Google Scholar
• Brandt, S. D., Sumnall, H. R., Measham, F., & Cole, J. (2010). Second generation mephedrone: The confusing case of NRG-1. British Medical Journal, 341.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., King, L. A., & Nutt, D. J. (2011). A Web-based survey on mephedrone. Drug and Alcohol Dependence, 118(1), 19–22.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2011). Emergency department visits after use of a drug sold as “bath salts”—Michigan, November 13, 2010–March 31, 2011. Morbidity and Mortality Weekly Report, 60(19), 624–627.
   PubMedGoogle Scholar
• Coppola, M., & Mondola, R. (2012a). 3,4-methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicology Letters, 208(1), 12–15.
   PubMed Web of Science ®Google Scholar
• Coppola, M., & Mondola, R. (2012b). Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant food”. Toxicology Letters, 211(2), 144–149.
   PubMed Web of Science ®Google Scholar
• Cozzi, N. V., Sievert, M. K., Shulgin, A. T., Jacob, P., & Ruoho, A. E. (1999). Inhibition plasma membrane monoamine transporters by beta-ketoamphetamines. European Journal of Pharmacology, 381(1), 63–69.
   PubMed Web of Science ®Google Scholar
• Davies, S., Wood, D. M., Smith, G., Button, J., Archer, R., Hold, D. W., & Dargan, P. I. (2010). Purchasing “legal highs” on the Internet: Is there consistency in what you get? QJM, 103(7), 489–493.
   PubMed Web of Science ®Google Scholar
• Dorairaj, J. J., Healy, C., McMenamin, M., & Eadie, P. A. (2012). The untold truth about “bath salts” highs: A case series demonstrating local tissue injury. Journal of Plastic, Reconstructive and Aesthetic Surgery, 65(2), e37–e41.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. (2011, April). Microgram Bulletin, 44(4), 31–37. Washington, D.C.: US Dept of Justice, Drug Enforcement Administration. Retrieved from http://www.dea.gov/pr/micrograms/2011/mg0411.pdf
   Google Scholar
• Frison, G., Gregio, M., Zamengo, L., Zancanaro, F., Frasson, S., & Sciarrone, R. (2011). Gas chromatography/mass spectrometry determination of mephedrone in drug seizures after derivatization with 2,2,2-trichloroethyl chloroformate. Rapid Communications in Mass Spectrometry, 25(2), 387–390.
   PubMed Web of Science ®Google Scholar
• Gardner, A. (2011, February). Hallucinogens legally sold as “bath salts” a new threat. Retrieved from http://health.usnews.com/health-news/family-health/brain-and-behavior/articles/2011/02/04/hallucinogens-legally-sold-as-bath-salts-a-new-threat
   Google Scholar
• Gibbons, S., & Zloh, M. (2010). An analysis of the “legal high” mephedrone. Bioorganic and Medicinal Chemistry Letters, 20(14), 4135–4139.
   PubMed Web of Science ®Google Scholar
• Hunterdon Drug Awareness Program. (2011). Comprehensive drug information on MDPV, mephedrone (“bath salts”). Retrieved from www.hdap.org/mdpv.html
   Google Scholar
• Kehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Silvertsson, T., Nyberg, F., & Yoshitake, T. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus acumbens of awake rats. British Journal of Pharmacology, 164, 1949–1958.
   PubMed Web of Science ®Google Scholar
• Kikura-Hanajiri, R., Kawamura, M., Saisho, K., Kodama, Y., & Goda, Y. (2007). The disposition into hair of new designer drugs; methylone, MBDB and methcathinone. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 855(2), 121–126.
   PubMed Web of Science ®Google Scholar
• Leo, R. J., & Goel, R. (2012). The delirious substance abuser. Current Psychiatry, 11(1), 58–67.
   Google Scholar
• National Conference of State Legislatures. (2012). Synthetic drug threats. Retrieved from http://www.ncsl.org/issues-research/justice/synthetic-drug-threats.aspx
   Google Scholar
• Newcombe, R. (2009). Mephedrone: Use of mephedrone (M-Cat, Meow) in Middlesbrough. Manchester, UK: Lifeline.
   Google Scholar
• Oyemade, A. (2010). Meow meow or miaowmiaow: A new drug of concern. Psychiatry (Edgemont), 7(12), 10.
   PubMedGoogle Scholar
• Prosser, J. M., & Nelson, L. S. (2012). The toxicology of bath salts: A review of synthetic cathinones. Journal of Medical Toxicology, 8(1), 33–42.
   PubMedGoogle Scholar
• Psychonaut WebMapping Research Group. (2009a). MDPV report. London, UK: Institute of Psychiatry, King's College London.
   Google Scholar
• Psychonaut WebMapping Research Group. (2009b). Mephedrone report. London, UK: Institute of Psychiatry, King's College London.
   Google Scholar
• Ramsey, J., Dargan, P. I., Smyllie, M., Davies, S., Button, J., Holt, D. W., & Wood, D. M. (2010). Buying “legal” recreational drugs does not mean that you are not breaking the law. QJM, 103(10), 777–783.
   PubMed Web of Science ®Google Scholar
• Regan, L., Mitchelson, M., & MacDonald, C. (2010). Mephedrone toxicity in a Scottish emergency department. Emergency Medicine Journal, 28(12), 1055–1058.
   PubMed Web of Science ®Google Scholar
• Ross, E. A., Watson, M., & Goldberger, B. (2011). “Bath salts” intoxication. New England Journal of Medicine, 365, 967–968.
   PubMed Web of Science ®Google Scholar
• Schmidt, M. M., Sharma, A., Schifano, F., & Feinmann, C. (2010). “Legal highs” on the net—evaluation of UK-based Websites, products and product information. Forensic Science International, 206(1–3), 92–97.
   PubMed Web of Science ®Google Scholar
• Smith, C., Cardile, A. P., & Miller, M. (2011). Bath salts as a “legal high.” The American Journal of Medicine, 124(11), e7–e8.
   PubMed Web of Science ®Google Scholar
• Spiller, H. A., Ryan, M. L., Weston, R. G., & Jansen, J. (2011). Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clinical Toxicology (Phila), 49(6), 499–505.
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O., & Schifano, F. (2011). Mephedrone, new kid for the chop? Addiction, 106(1), 154–161.
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., Mitcheson, L. R., & Marsden, J. (2010). Mephedrone: Still available and twice the price. Lancet, 376(9752), 1537.
   PubMed Web of Science ®Google Scholar
• Wissenback, D. K., Meyer, M. R., Remane, D., Phillip, A. A., Weber, A. A., & Maurer, H. H. (2011). Drugs of abuse screening in urine as part of a metabolite-based LC-MS(n) screening concept. Analytical and Bioanalytical Chemistry, 400(10), 3481–3489.
   PubMed Web of Science ®Google Scholar